Kirsten Drejer

Curasight is built on more than a decade of research in PET imaging in cancer diseases at the University of Copenhagen and Rigshospitalet. Part of our company strategy is focused on the discovery and development of novel radiopharmaceuticals for improved diagnose, risk-stratification and treatment monitoring in cancer diseases using PET imaging. Our current PET ligand discovery research program and our academic collaborations are focused on discovering and developing disease-specific PET ligands for multiple cancer indications. Another part of our strategy is to develop partnerships with larger pharmaceutical or biotechnology firms that improve our ability to move new PET ligands through the late stage clinical trials and to bring them into the marketplace.

Denmark´s Export and Investment fund is a new, state-owned fund which proves a single point of contact to all Danish companies in need of state financed risk capital. We cover both the entrepreneur, small and medium-sized companies who need capital to unfold their full potential, and export companies who wish to conquer new or emerging markets. We can guide you all the way, from the company´s tentative beginnings through substantial growth to entry into the global markets with export guarantees and stock market listings, because our mission is to help to grow the Danish economy and green the globe.

Curasight is built on more than a decade of research in PET imaging in cancer diseases at the University of Copenhagen and Rigshospitalet. Part of our company strategy is focused on the discovery and development of novel radiopharmaceuticals for improved diagnose, risk-stratification and treatment monitoring in cancer diseases using PET imaging. Our current PET ligand discovery research program and our academic collaborations are focused on discovering and developing disease-specific PET ligands for multiple cancer indications. Another part of our strategy is to develop partnerships with larger pharmaceutical or biotechnology firms that improve our ability to move new PET ligands through the late stage clinical trials and to bring them into the marketplace.

Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a Danish biotechnology company on a mission to change lives with next generation peptide medicines. In our effort to reach our goals bonding is at the core of everything we do. Let it be discovering and developing the best new peptide drugs for patients, engaging with partners or connecting with each other. This has led to more than 10 drug candidates invented by Zealand having advanced into clinical development, of which two have reached the market. Zealand’s current pipeline of internal product candidates focus on specialty gastrointestinal and metabolic diseases. Additionally, the portfolio includes clinical license collaboration with Boehringer Ingelheim and pre-clinical license collaboration with Alexion Pharmaceuticals. Zealand is based in Copenhagen (Søborg), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or bond with us through LinkedIn or Twitter @ZealandPharma.

lyhne & co. skaber kreativ kundekommunikation og har en ambition om at være branchens førende kommunikationsbureau, hvad angår detail og detaljeret business-to-business. lyhne & co. arbejder ud fra en systematisk arbejdsmetode med det formål at indsamle viden og facts om forbrugernes adfærd. Den viden vi indsamler, bruger vi til at skabe veldokumenterede kommunikationsløsninger offline som online. lyhne & co. kombinerer traditionel markedsanalyse med antropologiske observationer, hvilket gør det muligt at fastlægge forbrugernes faktiske adfærd og målrette kommunikationen dertil.

Transforming scientific advancements into better Life Science solutions for tomorrow. Bioneer is a trusted strategic R&D partner to biotech and pharmaceutical companies, founded in 1982. We are a Danish innovative specialty CRO, creating customized research service solutions that meet your needs. We help you develop and produce your promising early drug candidates from as early on as their inception, and we generate key early insights into their mechanisms, efficacy and safety. As your extended R&D team and trusted strategic partner, we bring value with our unique know-how and advanced technologies. With a staff of dedicated and highly skilled employees, state-of-the-art facilities in our two sites in the Copenhagen area, and a history of nearly 40 years of operation, Bioneer is fit to fulfil its dual role as a commercial entity with a societal obligation.